§2. Establishment of Abraham Accords Office within Food and Drug Administration
This section establishes the Abraham Accords Office within the Food and Drug Administration (FDA), to be headed by a director, located in an Abraham Accords country (i.e., a country identified by the Department of State as having signed the Abraham Accords Declaration), and staffed with FDA personnel as needed. Not later than two years after enactment, the HHS Secretary, acting through the FDA Commissioner and in consultation with Abraham Accords countries and U.S. diplomatic and security personnel, must select the office's location and establish the office. The office must (1) provide technical assistance to regulatory partners in Abraham Accords countries on strengthening oversight and converging requirements for FDA-regulated products, including good manufacturing practices for medical products; (2) facilitate interactions between the FDA and interested parties in those countries by sharing information on U.S. regulatory pathways and obtaining feedback on research, development, and manufacturing of regulated products; and (3) perform other necessary functions, subject to national security recommendations. Not later than three years after enactment, the HHS Secretary must report to Congress on the office, including an evaluation of manufacturers' progress toward FDA regulatory conformance in Abraham Accords countries, a numerical count of facilitated interactions, a summary of technical assistance provided, and recommendations for improved coordination.